Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
1.
Laeknabladid ; 104(1): 19-26, 2018 Jan.
Artigo em Islandês | MEDLINE | ID: mdl-29303110

RESUMO

This article discusses endovascular thrombectomy in acute ischemic stroke. This treatment is vascular medicine's most significant leap in years. This treatment is complicated, and various technical aspects are discussed. Close cooperation is required between different specialties since patient selection for treatment is complex. Interventionists need close collaboration with stroke neurologists. Government needs to be involved as this treatment mandates structural changes which will incur more manpower and financial resources. Telemedicine is also discussed as it has been shown to be advantageous for augmenting thrombolytic administration for acute ischemic stroke. Due to technical advances, it has been easier to provide such service, but hurdles need to be resolved so it can be fully implemented. It is likely that telemedi-cine will also play a role in thrombectomy. This article proposes how thrombectomy could be delivered in Iceland. It will prove difficult to provide such complex treatment in a scattered population of 343.000 people where expertise is limited to one or two sites. It is important to remember, that coronary intervention was a formidable challenge at one time, but it was accomplished. Can we learn from that experience?


Assuntos
Isquemia Encefálica/terapia , Prestação Integrada de Cuidados de Saúde/organização & administração , Procedimentos Endovasculares/métodos , Trombose Intracraniana/terapia , Acidente Vascular Cerebral/terapia , Telemedicina/métodos , Trombectomia/métodos , Terapia Trombolítica/métodos , Isquemia Encefálica/diagnóstico , Isquemia Encefálica/epidemiologia , Avaliação da Deficiência , Procedimentos Endovasculares/efeitos adversos , Humanos , Islândia/epidemiologia , Trombose Intracraniana/diagnóstico , Trombose Intracraniana/epidemiologia , Acidente Vascular Cerebral/diagnóstico , Acidente Vascular Cerebral/epidemiologia , Trombectomia/efeitos adversos , Terapia Trombolítica/efeitos adversos , Resultado do Tratamento
2.
Stroke ; 48(10): 2678-2685, 2017 10.
Artigo em Inglês | MEDLINE | ID: mdl-28830976

RESUMO

BACKGROUND AND PURPOSE: The associations of individual long-chain n-3 polyunsaturated fatty acids with incident ischemic stroke and its main subtypes are not well established. We aimed to investigate prospectively the relationship of circulating eicosapentaenoic acid, docosapentaenoic acid (DPA), and docosahexaenoic acid (DHA) with risk of total ischemic, atherothrombotic, and cardioembolic stroke. METHODS: We measured circulating phospholipid fatty acids at baseline in 3 separate US cohorts: CHS (Cardiovascular Health Study), NHS (Nurses' Health Study), and HPFS (Health Professionals Follow-Up Study). Ischemic strokes were prospectively adjudicated and classified into atherothrombotic (large- and small-vessel infarctions) or cardioembolic by imaging studies and medical records. Risk according to fatty acid levels was assessed using Cox proportional hazards (CHS) or conditional logistic regression (NHS, HPFS) according to study design. Cohort findings were pooled using fixed-effects meta-analysis. RESULTS: A total of 953 incident ischemic strokes were identified (408 atherothrombotic, 256 cardioembolic, and 289 undetermined subtypes) during median follow-up of 11.2 years (CHS) and 8.3 years (pooled, NHS and HPFS). After multivariable adjustment, lower risk of total ischemic stroke was seen with higher DPA (highest versus lowest quartiles; pooled hazard ratio [HR], 0.74; 95% confidence interval [CI], 0.58-0.92) and DHA (HR, 0.80; 95% CI, 0.64-1.00) but not eicosapentaenoic acid (HR, 0.94; 95% CI, 0.77-1.19). DHA was associated with lower risk of atherothrombotic stroke (HR, 0.53; 95% CI, 0.34-0.83) and DPA with lower risk of cardioembolic stroke (HR, 0.58; 95% CI, 0.37-0.92). Findings in each individual cohort were consistent with pooled results. CONCLUSIONS: In 3 large US cohorts, higher circulating levels of DHA were inversely associated with incident atherothrombotic stroke and DPA with cardioembolic stroke. These novel findings suggest differential pathways of benefit for DHA, DPA, and eicosapentaenoic acid.


Assuntos
Isquemia Encefálica/sangue , Doenças Cardiovasculares/sangue , Ácidos Graxos Ômega-3/sangue , Embolia Intracraniana/sangue , Trombose Intracraniana/sangue , Acidente Vascular Cerebral/sangue , Adulto , Idoso , Idoso de 80 Anos ou mais , Biomarcadores/sangue , Isquemia Encefálica/diagnóstico , Isquemia Encefálica/epidemiologia , Doenças Cardiovasculares/diagnóstico , Doenças Cardiovasculares/epidemiologia , Estudos de Casos e Controles , Estudos de Coortes , Feminino , Seguimentos , Humanos , Incidência , Arteriosclerose Intracraniana/sangue , Arteriosclerose Intracraniana/diagnóstico , Arteriosclerose Intracraniana/epidemiologia , Embolia Intracraniana/diagnóstico , Embolia Intracraniana/epidemiologia , Trombose Intracraniana/diagnóstico , Trombose Intracraniana/epidemiologia , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Distribuição Aleatória , Fatores de Risco , Acidente Vascular Cerebral/diagnóstico , Acidente Vascular Cerebral/epidemiologia , Estados Unidos/epidemiologia
3.
Chin Med J (Engl) ; 129(11): 1291-7, 2016 Jun 05.
Artigo em Inglês | MEDLINE | ID: mdl-27231165

RESUMO

BACKGROUND: The incidence of diabetic nephropathy (DN) increases year by year. However, clinical characteristics of DN patients on maintenance hemodialysis (MHD) were rarely reported in China. The purpose of this study was to examine the clinical characteristics of the DN patients on MHD in Anhui Province, Eastern China. METHODS: The clinical data of MHD patients in the hemodialysis centers of 26 hospitals in Anhui Province from January 1, 2014, to March 31, 2014, were examined. The differences between DN patients and non-DN patients were compared regarding vascular access, nutritional status, mineral and bone disorder, and other indexes. RESULTS: Among the selected 2768 adult MHD patients, 427 had DN. The incidence of hypertension, coronary heart disease, and cerebral thrombus in DN patients was 94.1%, 21.5%, and 15.0%, respectively, which were higher than those in non-DN patients (P < 0.001). Category of vascular access for hemodialysis in DN patients was arteriovenous fistula (AVF) (87.4% [373/427]) and tunneled cuffed catheter (TCC) (11.2% [48/427]). The percentage of AVF was significantly lower than that of non-DN patients (P < 0.001), and percentage of TCC was significantly higher than that of non-DN patients (P < 0.001). Hemoglobin achievement rate in DN patients was 32.0%. The incidence of hypoalbuminemia was 24.7%, significantly higher than that in non-DN patients (P < 0.001). The achievement rate of the target range in mineral values was 55.9% in corrected serum calcium level, 30.1% in serum phosphorus level, and 49.3% in intact parathyroid hormone (iPTH) level in DN patients. Compared with non-DN patients, the achievement rate of serum phosphorus was significantly higher in DN patients. CONCLUSIONS: DN patients on MHD in Anhui province exhibited different clinical characteristics compared to non-DN hemodialysis patients. They presented higher percentage in TCC use and cardiovascular complication, lower serum albumin and iPTH levels than those in non-DN patients.


Assuntos
Nefropatias Diabéticas/epidemiologia , Diálise Renal , Idoso , Cálcio/sangue , China , Doença das Coronárias/sangue , Doença das Coronárias/epidemiologia , Doença das Coronárias/fisiopatologia , Estudos Transversais , Nefropatias Diabéticas/sangue , Nefropatias Diabéticas/fisiopatologia , Feminino , Humanos , Hipertensão/sangue , Hipertensão/epidemiologia , Hipertensão/fisiopatologia , Trombose Intracraniana/sangue , Trombose Intracraniana/epidemiologia , Trombose Intracraniana/fisiopatologia , Masculino , Pessoa de Meia-Idade , Hormônio Paratireóideo/sangue , Fósforo/sangue
5.
J Cardiovasc Electrophysiol ; 23(6): 567-73, 2012 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-22313240

RESUMO

BACKGROUND: The incidence of cerebral thromboembolism after pulmonary vein isolation (PVI) ranges from 2% to 14%. This study investigated the incidence of cerebral thromboembolism after complex fractionated atrial electrogram (CFAE) ablation with or without PVI. METHODS: One hundred consecutive atrial fibrillation (AF) patients (50 paroxysmal and 50 persistent, including 10 longstanding) who underwent CFAE ablation combined with (n = 41, PVI+CFAE group) or without (n = 59, CFAE group) PVI were studied. Coronary angiography (CAG) was conducted with AF ablation in 5 cases in which coronary artery stenosis was suspected on 3D-computed tomography. PVI was performed before CFAE ablation without circular catheter during AF. After termination of AF, additional ablation was performed to complete PVI with a circular catheter. All patients underwent cerebral magnetic resonance imaging (MRI) including diffusion-weighted MRI and T2-weighted MRI the day after ablation. RESULTS: New thromboembolism was detected in 7.0%, and there was no significant difference between the 2 strategies (7.3% in PVI+CFAE group, 6.8% in CFAE group). CHADS2 score (1.6 ± 1.0 vs 0.8 ± 0.9, P < 0.05), left atrial volume (LAV; 83.8 ± 27.1 vs 67.8 ± 21.8, P < 0.05), and left ventricular ejection fraction (LVEF, 53.1 ± 9.2 vs 65.1 ± 9.7, P < 0.01) were significantly different when comparing patients with or without thromboembolism. In multivariate analysis, LVEF (odds ratio [OR], 0.92; 95% confidence interval [CI], 0.84-0.99; P < 0.05) and concomitant CAG (OR 18.82; 95% CI, 1.77-200.00; P < 0.05) were important predictors of new cerebral thromboembolism. CONCLUSIONS: The incidence of cerebral microthromboembolism after CFAE ablation was not greater than previous reports in PVI. Cautious management is required during AF ablation, especially in the patients with low LVEF.


Assuntos
Fibrilação Atrial/cirurgia , Ablação por Cateter/efeitos adversos , Técnicas Eletrofisiológicas Cardíacas , Embolia Intracraniana/epidemiologia , Trombose Intracraniana/epidemiologia , Idoso , Idoso de 80 Anos ou mais , Doenças Assintomáticas , Fibrilação Atrial/diagnóstico , Fibrilação Atrial/epidemiologia , Fibrilação Atrial/fisiopatologia , Distribuição de Qui-Quadrado , Angiografia Coronária/métodos , Estenose Coronária/diagnóstico por imagem , Estenose Coronária/epidemiologia , Imagem de Difusão por Ressonância Magnética , Feminino , Humanos , Incidência , Embolia Intracraniana/diagnóstico , Trombose Intracraniana/diagnóstico , Japão , Masculino , Pessoa de Meia-Idade , Análise Multivariada , Razão de Chances , Valor Preditivo dos Testes , Medição de Risco , Fatores de Risco , Volume Sistólico , Fatores de Tempo , Tomografia Computadorizada por Raios X , Função Ventricular Esquerda
6.
Rev. neurol. (Ed. impr.) ; 37(11): 1040-1043, 1 dic., 2003. ilus
Artigo em Espanhol | IBECS | ID: ibc-128654

RESUMO

Introducción. La hiperhomocisteinemia moderada es un factor de riesgo independiente para la arteriosclerosis y la enfermedad tromboembólica. En los últimos años existe un interés creciente por determinar su relación causal; sin embargo, se recogen pocos casos en la literatura asociados a la trombosis venosa cerebral. Caso clínico. Mujer de 21 años que toma anticonceptivos orales. Una semana antes del ingreso, comienza con cefalea opresiva biparietal continua que interfiere el sueño, acompañada de nausea y vómitos, y que empeora con las maniobras de Valsalva. En la exploración neurológica destaca un papiledema bilateral de predominio izquierdo. El resto de la exploración fue normal. En distintas pruebas de neuroimagen –tomografía computarizada (TAC), resonancia magnética (RM) y angiorresonancia magnética– se objetiva una trombosis de seno transverso izquierdo. Se realizó un estudio inmunológico (ANA, ANCA y anticuerpos antifosfolípidos), que fue normal. En el estudio de hipercoagulabilidad, la concentración de homocisteína resultó elevada de forma repetida. Tras un tratamiento anticoagulante, y medidas antiedema, evolucionó satisfactoriamente. Discusión. El 70% de las trombosis de seno venoso se deben a estados protrombóticos, entre ellos la hiperhomocisteinemia moderada. Su patogénesis parece ser multifactorial, incluido el daño endotelial directo. Por otra parte, se comenta el papel facilitador de los anticonceptivos orales sobre estados protrombóticos subclínicos, además de discutirse las posibilidades terapéuticas con ácido fólico (AU)


Introduction. Moderate hyperhomocystinemia is a causal risk factor for atherosclerosis and venous thromboembolism. Recent researches have tried to find out a causal relationship. However, only a small number of cases have been reported on hyperhomocysteinemia and cerebral venous thrombosis in the world medical literature. Case report. We present the case of a 21 years old woman, and oral contraceptives taker, who consulted for a one week clinical picture of biparietal headache, nausea and vomiting. Examination revealed bilateral papilledema, and subsequent CT scan, MRI and MR angiography showed thrombosis of the left lateral sinus. Immunologic tests (antinuclear antibodies, antiphospholipid antibodies) were negative. Hypercoagulability studies showed persistent homocysteine high levels. The patient improved and was discharged after treatment with anticoagulants and therapeutic measures against brain edema. Discussion. The 70 percent of the patients with thrombosis of the cerebral venous sinuses present hypercoagulable states, including moderate hyperhomocysteinemia. Several mechanisms are proposed for venous thrombosis in hyperhomocysteinemia, homocysteine induced endothelial dysfunction between others. Otherwise, oral contraceptives can increase the risk of venous thrombosis in other prothrombotic conditions. Folic acid and vitamins supplementation therapy are commented (AU)


Assuntos
Humanos , Feminino , Trombose Intracraniana/complicações , Trombose Intracraniana/diagnóstico , Trombose Intracraniana/epidemiologia , Hiper-Homocisteinemia/complicações , Hiper-Homocisteinemia/diagnóstico , Anticoncepcionais Orais/administração & dosagem , Hiper-Homocisteinemia/imunologia , Hiper-Homocisteinemia/terapia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA